{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"The MTD was defined as the highest dose level at which no more than one out of six participants experienced DLT. DLT was defined using NCI CTCAE Version 4.03 as any grade 3 or 4 hematemesis, hemoptysis, hematochezia, bright red blood per rectum, epistaxis, gingival bleeding, hemarthrosis, haematuria, uncontrollable menses, or any other bleeding thought to be significant as per assessment of the investigator, regardless of grade.","groups":[{"description":"Participants received, MORAb-066 0.1 or 0.3 or 1 or 2 or 3 mg/kg, infusion intravenously, on Days 1, 8, 15, and 22, in a 28-day treatment cycle until disease progression, the participant discontinuation due to unacceptable toxicity, withdrawal by participants, or discontinuation by study physician decision.","id":"OG000","title":"MORAb-066: All Participants"}],"paramType":"NUMBER","populationDescription":"The DLT evaluable set included all participants who were evaluable for the DLTs in first cycle and had taken at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Cycle length=28 days)","title":"Maximum Tolerated Dose (MTD)","type":"SECONDARY","unitOfMeasure":"mg/kg"}